1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. (miriam.mukuru@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 09:19 ET (13:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.